Building Insights for Patient Focused Drug Development: Understanding Patient Desires and Barriers

Published July 12th, 2022 | 3 Minute Read

By Blaine Cloud
Senior VP, Insights
Health Union

In 2019, the last calendar year before the COVID-19 pandemic, over forty (40) articles* were published involving clinical studies with decentralized, remote or hybrid trials. During the pandemic, it is likely that the percent of trials with full or partially decentralized site visits increased, an idea that is further supported by research conducted by McKinsey that was published in 2021.  Action taken by the FDA also signals greater acceptance of decentralized trial components and a push for greater diversity of trial subjects.

Despite these positive changes in the industry, sponsors continue to have recruitment challenges with completing trials on time and on-budget.

One way to minimize these challenges is to bring the voice of the patient to trial design and execution; a portion of what the FDA calls Patient Focused Drug Development (PFDD). 

As experts in clinical services, Health Union engages patients and caregivers in patient focused drug development conversations. Through our social health networks, we can access patients who could become eligible study subjects, acting as a “meta advocacy” organization as some members are patient leaders and advocates within their respective condition advocacy associations. We assess patients’ motivations and desires around clinical trials and share this information with our partners to help bring meaningful and positive change to clinical trial development, recruitment, and execution.

In two Health Union survey samples of 1,925 and 607 US patients respectively, whose chronic conditions would have potentially qualified them for a clinical trial, we studied what makes clinical trial enrollment attractive to patients. In the years just prior to the COVID pandemic, patients were drawn to enroll in trials for personal and altruistic reasons, highlighted by the following:

  • Clinical trial interest is driven by hope of finding a therapy that may finally, or adequately, provide effectiveness for their condition (86% of those surveyed) whereas only 11% of patients felt a trial is only a means of gaining financial access to therapy
  • Of the 17% of chronic patients who had participated in a clinical trial, 43% learned about the trial from their healthcare provider and only 6% searched and found the trial on their own. 
    • A more recent 2020 survey found that online communities and support groups appeared to be an increasing source of trial awareness, with 11% of participants learning about them in this way)
  • Past trial participants wished they had access to key information that was never provided including: 
    • My data after the trial: 41% 
    • Aggregate study results: 37% 
    • Knowledge of treatment plan after the trial: 28% 
    • Who the study sponsor was before the trial started: 23%
  • Among those taking the most recent Health Union survey (n=607), reasons for not participating in a clinical trial included:
    • The exclusion criteria were too restrictive for me to qualify: 23%
    • The site was too far away from home: 21%
    • Fear of an untested/new medication: 14%

Related Articles

The Online Health Community Model: Role and Importance in Marketing Research

Recognizing the growing role of patients and caregivers in healthcare decisions, pharmaceutical and biotechnology companies are looking for ways to easily and accurately infuse the voice of the patient and caregiver into strategic marketing decisions. The need to do so quickly, efficiently and accurately, particularly with hard-to-reach patients, creates a need for online patient communities. However, the approaches and philosophies behind these communities can vary greatly.

Childhood onset migraine and adult outcomes: A retrospective survey

Partnering with University of Chung-Ang and University of Colorado, this abstract showcases data from Health Union’s Migraine In America 2015 survey.

Health Union Announces Acceptance to Present at NCCN Annual Conference 2019

Results from the qualitative analysis demonstrate that people with cancer are broadly misinformed about the benefits of palliative care and have some confusion around the timing and components of hospice care.

On an ongoing basis, Health Union assesses perceptions of clinical trial interest and clinical trial features within our online social health communities and shares findings with industry partners. 

If your organization is looking to understand and address patient needs during early stage clinical development to enhance trial design, recruitment tactics, and retention efforts, we invite you to contact us today. 

*Source: PubMed internal search

Related Articles

Survey Provides Deep Dive into Deep Infiltrative Endometriosis

Survey Provides Deep Dive into Deep Infiltrative Endometriosis

Deep infiltrative endometriosis (DIE) impacts more than half of Health Union’s “Endometriosis In America” survey respondents.

COVID-19 Resource Center for Pharma Marketers

Browse through data-driven COVID-19 resources for pharma marketing to see how the pandemic is affecting people living with chronic health conditions.

People are concerned about returning back to normal during COVID-19.

People with Chronic Conditions Concerned About “Returning to Normal” During Pandemic

Although frustrated by COVID-19’s physical and mental toll, people with chronic conditions approach the idea of “returning to normal” with concern.